Are peptides legal in South Korea?
Sourced guide to the legal status of peptides in South Korea, refreshed automatically from live research.
Overall Status: Restricted
Short answer: Peptides are restricted in South Korea: peptide medicines that have been formally approved (such as GLP-1 class obesity/diabetes drugs) are prescription-only pharmaceuticals regulated by the Ministry of Food and Drug Safety (MFDS), while unapproved 'research' peptides such as BPC-157 and TB-500 have no MFDS marketing approval and cannot be lawfully sold, prescribed, or marketed for human use.
Important: This information is for educational purposes only and does not constitute legal advice. Laws and enforcement policies change. Consult a qualified attorney for specific legal guidance.
Overview
South Korea restricts peptide products through the Ministry of Food and Drug Safety (MFDS), which classifies legitimate peptide drugs as prescription pharmaceuticals and has specifically warned that GLP-1 class obesity treatments must only be used under a doctor's prescription. The MFDS also maintains dedicated quality-evaluation guidelines for synthetic peptide drugs, showing that any peptide marketed as medicine must go through its formal drug approval pathway. Peptides sold as unregulated 'research chemicals' (e.g., BPC-157, TB-500) fall outside any approved-drug category, meaning no clear legal pathway exists for their human use or retail sale in Korea.
Key Points
- South Korea's Ministry of Food and Drug Safety (MFDS) has publicly stated that GLP-1 class obesity treatments are prescription-only drugs that must be used by obesity patients under a medical professional's prescription, in response to reports of rising misuse. [1]
- The MFDS maintains a dedicated quality-evaluation guideline specifically for synthetic peptide drugs, confirming that peptide-based medicines in South Korea are treated as a distinct pharmaceutical category subject to formal MFDS quality and approval review. [2]
- The MFDS abolished its prior administrative approach that allowed low-molecular-weight synthetic peptide salt formulations to be approved as chemical (rather than biologic) drugs, indicating the agency continues to actively revise how peptide drugs are classified and reviewed. [3]
- Consumers can look up whether any specific peptide product has MFDS drug approval through the agency's public 의약품안전나라 (Drug Safety Nara) portal, which lists officially approved medicines available in South Korea. [5]
- No South Korea-specific customs or personal-import rule for peptides such as BPC-157 or TB-500 was found in the sources reviewed; travelers should assume that unapproved peptide substances face the same restrictions as other unapproved prescription drugs entering Korea, which generally require a prescription or MFDS import permit, but this has not been confirmed with a primary source. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
- No specific South Korean enforcement action (fines, seizures, or prosecutions) targeting BPC-157, TB-500, or similar unapproved research peptides was found in the sources reviewed, so the real-world enforcement pattern for these specific compounds remains unconfirmed. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
Peptide-by-peptide status in South Korea
| BPC-157 | BPC-157 does not appear as an MFDS-approved drug in South Korea, and no source was found confirming a specific legal pathway for its human use, so its status as an unapproved research peptide in Korea remains unconfirmed rather than clearly settled. |
|---|
| Semaglutide / Tirzepatide (GLP-1 class) | GLP-1 class weight-loss and diabetes peptide drugs are legal in South Korea only as prescription-only medicines, with the MFDS explicitly warning that they must be used by obesity patients strictly under a doctor's prescription due to rising misuse. [1] |
|---|
| TB-500 (Thymosin beta-4) | No MFDS approval or South Korea-specific regulatory statement on TB-500 was found in the sources reviewed, so its legal status as an unapproved research peptide in Korea could not be confirmed with a direct source. |
|---|
| Human Growth Hormone (HGH / somatropin) | No South Korea-specific source confirming somatropin's prescription-only classification was located during this research, so while it is widely regulated as a prescription biologic elsewhere, its specific Korean legal status here is unsourced. |
|---|
Last researched: 2026-09-10
Frequently asked questions
No, you cannot legally buy MFDS-approved GLP-1 class peptide drugs (semaglutide-type medicines) in South Korea without a prescription, because the Ministry of Food and Drug Safety has explicitly classified them as prescription-only medicines to be used under a doctor's supervision.
[1]
It is unclear whether BPC-157 has any lawful sales pathway in South Korea, since no MFDS drug approval or specific customs ruling for BPC-157 was found in available sources; buyers should not assume it is treated the same as an approved medicine.
No confirmed South Korea-specific personal-import rule for peptides was found in this research; travelers carrying prescription peptide medicines like GLP-1 drugs should generally expect to need a valid prescription, consistent with the MFDS's classification of these as prescription-only drugs, but this has not been verified against a customs-specific source.
[1]
No specific South Korea telehealth-prescribing rule for peptide obesity drugs was found in this research; what is confirmed is that the MFDS requires these drugs to be used only under a medical professional's prescription, regardless of the mode of consultation.
[1]
Peptide drugs in South Korea are subject to a dedicated MFDS quality-evaluation guideline for synthetic peptide medicines, meaning any peptide marketed as a drug must meet specific quality-review criteria set by the regulator before it can be approved.
[2]